2021 CMSC Annual Meeting

Tag: Belgium

Poster-Quality of Life and Outcomes

Patient-Reported Outcome Measures in Multiple Sclerosis Clinical Trials: Critical Assessment and Insights from People Living with Multiple Sclerosis

Background: Multiple sclerosis (MS) clinical trials often include patient-reported outcomes (PROs) to quantify treatment effects not...

Read More

Poster-Methods of Care

Remote Monitoring in MS – Initial Experience with Medical Device Icompanion

Background: In the last decade, many electronic health (eHealth) technologies have found their way to the field of multiple sclerosis (MS)....

Read More

Poster-Imaging

Influence of Imaging Parameters on MRI Contrast Using Qualitymetrix

Background: Acquiring brain magnetic resonance images (MRI) with sufficient tissue contrast is important for supporting diagnosis and...

Read More

Poster-Imaging

Compliance of a Real-World Dataset with the CMSC 2018 Guidelines

Background: Acquiring brain magnetic resonance images (MRI) in a standardized way, following CMSC guidelines, increases image consistency...

Read More

Poster-Disease-modifying Therapy

Opportunities and Pitfalls in the Assessment of Brain Atrophy in Dimethyl Fumarate-Treated Relapsing Multiple Sclerosis Patients Using Real-World Data

Background: The majority of real-world data (RWD) on disease-modifying treatments (DMTs) for multiple sclerosis (MS) is based on clinical...

Read More

Poster-Disease-modifying Therapy

Recently Diagnosed Treatment-Naive RRMS: 1-Year Safety Data from the Ocrelizumab Phase IIIb ENSEMBLE Study

Background: ENSEMBLE (NCT03085810) is a multicenter, open-label, single-arm Phase IIIb study evaluating the effectiveness and safety of...

Read More

Platform-Disease Modifying Therapies

Improvements in Work Productivity and Activity Impairment in Ocrelizumab-Treated Patients with RRMS: 2-Year Data from the CASTING Study

Background: The Work Productivity and Activity Impairment (WPAI) questionnaire is a patient-reported outcome that assesses percentage of...

Read More

Platform-Disease Modifying Therapies

Recently Diagnosed Early-Stage RRMS: Neda, ARR, Disability Progression, Serum Neurofilament and Safety: 1-Year Interim Data from the Ocrelizumab Phase IIIb ENSEMBLE Study

Background: Early treatment of multiple sclerosis (MS) and rapid onset of therapeutic effect provide long-term benefits on disease...

Read More